KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBIT Margin: 2010-2024

Historic EBIT Margin for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to -270.30%.

  • TherapeuticsMD's EBIT Margin rose 9736.00% to -109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was -61.80%, marking a year-over-year increase of 35649.00%. This contributed to the annual value of -270.30% for FY2024, which is 38431.00% up from last year.
  • As of FY2024, TherapeuticsMD's EBIT Margin stood at -270.30%, which was up 58.71% from -654.61% recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's EBIT Margin ranged from a high of 1.70% in FY2022 and a low of -3,092.77% during FY2021.
  • In the last 3 years, TherapeuticsMD's EBIT Margin had a median value of -270.30% in 2024 and averaged -307.74%.
  • Per our database at Business Quant, TherapeuticsMD's EBIT Margin slumped by 285,301bps in 2021 and then spiked by 309,447bps in 2022.
  • TherapeuticsMD's EBIT Margin (Yearly) stood at -239.77% in 2020, then plummeted by 285,301bps to -3,092.77% in 2021, then spiked by 309,447bps to 1.70% in 2022, then crashed by 65,631bps to -654.61% in 2023, then soared by 38,431bps to -270.30% in 2024.